StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) stock

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$36.34+0.00 (0.00%)

Close on Oct 19, 2026Market cap $1.46BP/E 103.8Yield –

Pacira BioSciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Pacira BioSciences's free cash flow for the twelve months ending Jun 30, 2026 was $179.52M, up 53.3% year over year. For fiscal 2025 it was $136.66M, down 23.5% from the year before. The highest annual figure on record is $178.75M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$136.66M-23.5%
FY2024Dec 31, 2024$178.75M+28.1%
FY2023Dec 31, 2023$139.49M+21.1%
FY2022Dec 31, 2022$115.20M+44.3%
FY2021Dec 31, 2021$79.85M+103.5%
FY2020Dec 31, 2020$39.23M-35.0%
FY2019Dec 31, 2019$60.36M+75.7%
FY2018Dec 31, 2018$34.36M–
FY2017Dec 31, 2017-$1.48M-116.9%
FY2016Dec 31, 2016$8.74M–
FY2015Dec 31, 2015-$12.27M-442.8%
FY2014Dec 31, 2014$3.58M–
FY2013Dec 31, 2013-$56.01M–
FY2012Dec 31, 2012-$88.39M–
FY2011Dec 31, 2011-$37.17M–
FY2010Dec 31, 2010-$31.65M–
FY2009Dec 31, 2009-$26.35M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$56.12M+502.5%
Q1 FY2026Mar 31, 2026$22.96M-14.7%
Q4 FY2025Dec 31, 2025$43.47M+40.2%
Q3 FY2025Sep 30, 2025$56.96M+14.3%
Q2 FY2025Jun 30, 2025$9.32M-82.0%
Q1 FY2025Mar 31, 2025$26.91M-41.8%
Q4 FY2024Dec 31, 2024$31.01M-32.3%
Q3 FY2024Sep 30, 2024$49.83M+21.4%
Q2 FY2024Jun 30, 2024$51.65M+28.8%
Q1 FY2024Mar 31, 2024$46.27M+268.3%
Q4 FY2023Dec 31, 2023$45.79M+25.3%
Q3 FY2023Sep 30, 2023$41.04M+9.5%
Q2 FY2023Jun 30, 2023$40.10M+121.9%
Q1 FY2023Mar 31, 2023$12.56M-45.6%
Q4 FY2022Dec 31, 2022$36.55M+160.1%
Q3 FY2022Sep 30, 2022$37.47M-20.6%
Q2 FY2022Jun 30, 2022$18.07M-7.7%
Q1 FY2022Mar 31, 2022$23.11M–
Q4 FY2021Dec 31, 2021$14.05M-56.4%
Q3 FY2021Sep 30, 2021$47.21M+47.5%
Q2 FY2021Jun 30, 2021$19.58M–
Q1 FY2021Mar 31, 2021-$992.00K–
Q4 FY2020Dec 31, 2020$32.26M+50.7%
Q3 FY2020Sep 30, 2020$32.02M+91.0%
Q2 FY2020Jun 30, 2020-$24.53M-218.4%
Q1 FY2020Mar 31, 2020-$516.00K-134.8%
Q4 FY2019Dec 31, 2019$21.41M+12.8%
Q3 FY2019Sep 30, 2019$16.76M+37.7%
Q2 FY2019Jun 30, 2019$20.71M+87.0%
Q1 FY2019Mar 31, 2019$1.48M–
Q4 FY2018Dec 31, 2018$18.98M+60.1%
Q3 FY2018Sep 30, 2018$12.18M–
Q2 FY2018Jun 30, 2018$11.08M–
Q1 FY2018Mar 31, 2018-$7.87M–
Q4 FY2017Dec 31, 2017$11.86M-4.9%
Q3 FY2017Sep 30, 2017-$8.23M-205.8%
Q2 FY2017Jun 30, 2017-$1.50M–
Q1 FY2017Mar 31, 2017-$3.61M–
Q4 FY2016Dec 31, 2016$12.47M–
Q3 FY2016Sep 30, 2016$7.78M–

More Pacira BioSciences figures

See a number that looks wrong?